CMTM3

Across TCGA pan-cancer cohorts, CMTM3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CMTM3 data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CMTM3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CMTM3 expression acts as an unfavorable survival marker.

PDAC, LUAD, and LSCC are the cancer types where CMTM3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.269	0.528	<.001	27	view →
LUAD	DFS	Tertile	All	0.270	0.784	.038	10	view →
LSCC	DFS	Median	II,III,IV	0.831	1.000	.003	6	view →
CCRCC	DFS	Median	All	0.457	0.723	.036	4	view →
GBM	DFS	Tertile	All	0.626	0.761	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CMTM3–PDAC (DFS)

Open the PDAC breakdown →